Renal Considerations in Critically Ill Hematopoietic Stem Cell Transplant Patients
Aklilu A, Renaghan A. Renal Considerations in Critically Ill Hematopoietic Stem Cell Transplant Patients. 2023, 351-364. DOI: 10.1007/978-3-031-28797-8_27.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAcute kidney injuryKidney injuryRisk factorsIncidence of AKIPrognosis of AKIHematopoietic stem cell transplant patientsPost-transplant risk factorsTransplant-associated thrombotic microangiopathyStem cell transplant patientsHepatic sinusoidal obstruction syndromePost-transplant complicationsChronic kidney diseaseIndependent risk factorSinusoidal obstruction syndromeCell transplant patientsKidney replacement therapyStem cell transplantationIntensive care unitHospital mortalityNephrotoxic medicationsRenal considerationsVentilator requirementEngraftment syndromeHSCT recipientsA randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes
Wilson F, Yamamoto Y, Martin M, Coronel-Moreno C, Li F, Cheng C, Aklilu A, Ghazi L, Greenberg J, Latham S, Melchinger H, Mansour S, Moledina D, Parikh C, Partridge C, Testani J, Ugwuowo U. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nature Communications 2023, 14: 2826. PMID: 37198160, PMCID: PMC10192367, DOI: 10.1038/s41467-023-38532-3.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAcute Kidney Injury OutcomesAlert groupNon-steroidal anti-inflammatory drugsComposite of progressionHours of randomizationMedications of interestAldosterone system inhibitorsClasses of medicationsProton pump inhibitorsRandomized clinical trialsAnti-inflammatory drugsClinical decision support systemNephrotoxic medicationsHospitalized adultsDiscontinuation ratesCertain medicationsPrimary outcomeSubstantial morbiditySystem inhibitorsPump inhibitorsParallel group